Janssen presents five year data of STELARA in treatment of Crohn’s Disease
Over half of the patients with moderately to severely active CD who were randomised to subcutaneous ustekinumab every eight weeks…
Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
